Ethos Technologies Inc. - Class A Common Stock (NQ:LIFE)

36.22 +1.22 (+3.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ethos Technologies Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

Ethos (LIFE) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Third-party channel revenue jumped 90% as the company scales its platform.

Via The Motley Fool

Topics Earnings

These Analysts Boost Their Forecasts On Ethos Technologies Following Upbeat Q2 Results ↗

August 04, 2026

Ethos Technologies Inc (NASDAQ: LIFE) reported strong Q2 results, beating earnings and sales estimates. FY26 sales guidance was also raised above expectations.

Via Benzinga

Ethos Technologies Inc. Class A Common Stock Q2 Earnings Call Highlights ↗

August 03, 2026

Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) reported second-quarter fiscal 2026 revenue of $189.6 million, up 113% from a year earlier, as growth accelerated across its...

Via MarketBeat

Topics Earnings

ETHOS TECHNOLOGIES INC CL-A (NASDAQ:LIFE) Revenue Beat and Profitability Surprise Masked by GAAP Loss and Stock Compensation ↗

May 06, 2026

Via Chartmill

Recap: aTyr Pharma Q4 Earnings ↗

March 14, 2024

Via Benzinga

aTyr Pharma's Earnings Outlook ↗

March 13, 2024

Via Benzinga

Analyst Expectations for aTyr Pharma's Future ↗

September 21, 2023

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

August 03, 2026

Via Chartmill

Ethos Technologies Shares Tumble As Bear Cave Takes Aim ↗

May 21, 2026

Shares of Ethos Technologies Inc (NASDAQ: LIFE) are trading sharply lower on Thursday after short-selling newsletter The Bear Cave published a highly critical report on the digital life insurance...

Via Benzinga

Ethos (LIFE) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Ethos (LIFE) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Initial Public Offering

The Latest Analyst Ratings for aTyr Pharma ↗

May 23, 2023

Via Benzinga

aTyr Pharma: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Where aTyr Pharma Stands With Analysts ↗

March 10, 2023

Via Benzinga

2 Small-Cap Biotech Stocks Well Positioned for a Breakout ↗

August 27, 2025

Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.

Via The Motley Fool

3 Innovation Stocks With Parabolic Upside Potential ↗

August 08, 2025

These three growth stocks might be deeply undervalued.

Via The Motley Fool

Topics Artificial Intelligence

1 Small-Cap Biotech Stock Poised for a Breakout ↗

August 06, 2025

This developmental biotech is nearing a key inflection point.

Via The Motley Fool

Topics Economy

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 ↗

June 05, 2024

These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.

Via InvestorPlace

LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

LIFE stock results show that aTyr Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 09, 2024

Via Benzinga

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition ↗

March 26, 2024

Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.

Via InvestorPlace

LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 ↗

March 14, 2024

LIFE stock results show that aTyr Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

The 3 Best Penny Stocks to Buy in February 2024 ↗

February 15, 2024

With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.

Via InvestorPlace

$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

August 02, 2023

The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks...

Via Benzinga

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst ↗

July 05, 2023

Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ: LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗

July 05, 2023

Via Benzinga

7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 ↗

June 28, 2023

Bard AI has consistently outperformed, and it has identified seven growth stocks that it believes will deliver triple-digit returns.

Via InvestorPlace

3 Stocks and Cryptos With the Highest Potential Returns ↗

May 07, 2023

If you're only worried about upside, these stocks and cryptos have some of the highest possible returns in the market.

Via InvestorPlace

7 Hot Growth Stocks Poised to Triple in 2023 ↗

May 05, 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.

Via InvestorPlace

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.